A reader comparing hormone medicines may encounter natural, bioidentical, generic and compounded as though they describe competing versions of the same idea. They do not. Some concern the ingredient's identity, some describe how a product is supplied, and others refer to a regulatory pathway. Confusing them makes an ordinary medication question unnecessarily difficult.
For progesterone, the useful distinction is between what the molecule is and what is known about the finished preparation. This article separates those questions using regulator explanations and a named product label. It does not choose a hormone plan for you or assume that a reassuring term resolves the benefits, risks and practical details of a prescription.
Read this article by section
Chemical identity does not specify the manufacturing pathway
The Prometrium label states that its progesterone is chemically identical to progesterone of human ovarian origin. It also explains that the ingredient is synthesized from a plant-derived starting material. These descriptions are compatible: laboratory manufacturing can produce a hormone with the same chemical structure as the hormone made in the body.
The distinction helps avoid a false choice between a natural molecule and a manufactured medicine. A plant origin does not mean the capsule contains unprocessed plant material, and identical structure does not mean the package reproduces the body's pattern of hormone production. Our micronization guide explains a separate physical-preparation term. None of these descriptors, by itself, specifies the full formulation, prescribed purpose or individual response.
Bioidentical is used for both approved and compounded products
ACOG's clinical consensus discusses bioidentical hormones in FDA-approved medicines as well as compounded preparations. It cautions against using the term to imply that custom preparations are necessarily safer or more effective. The FDA's menopause information likewise does not accept compounded bioidentical marketing as evidence of superiority over approved hormone products.
An advertisement that contrasts bioidentical treatment with all conventional medicine can therefore leave out an important category: approved medicines containing the same hormone identity. Ask whether the comparison concerns an actual ingredient difference, a different route or simply a different supply arrangement. Without that clarification, the word can make products look fundamentally different when the unresolved issue is the evidence for their finished formulations.
FDA approval evaluates a product, not a promotional adjective
The FDA's compounding explanation distinguishes compounded drugs from products that undergo approval review for safety, effectiveness and quality. Knowing that progesterone appears in an approved medicine does not mean every preparation containing progesterone has been approved. Nor does a licensed professional's involvement convert an unapproved compounded product into an approved one.
That difference deserves an explicit answer in a consultation. Ask whether the proposed medicine is an identifiable approved product or a compounded preparation, and why that choice is being considered. Our CoreAge review keeps the provider's oral micronized progesterone description separate from Prometrium's product record. A review should acknowledge missing formulation information instead of filling it with the details of a more familiar medicine.
A generic medicine is not another name for a compounded medicine
An FDA-approved generic follows an approval pathway with requirements concerning the active ingredient, strength, dosage form, route and bioequivalence to its reference product. The FDA's generic-drug explanation describes those standards and explains why approved generics can provide the same clinical benefit as their brand-name counterparts. That is a different regulatory situation from individualized compounding.
A lower advertised price or absence of a familiar brand name does not, by itself, establish an inferior hormone. Conversely, the word generic should not be accepted as proof of the exact product being supplied when a listing is incomplete. Ask the pharmacy to identify the medicine. Our offers comparison separates brand, generic and compounded pathways without assuming that a marketing category answers every product question.
There can be a reason to compound without proof of superiority
The FDA recognizes that compounding can meet a medical need when an approved medicine is unsuitable for a patient, including certain ingredient or formulation needs. ACOG nevertheless recommends against routinely using compounded bioidentical menopausal hormone therapy when approved formulations are available. An individual reason and a general claim of better treatment are different propositions.
If compounding is proposed, ask which need it addresses and what evidence supports the intended preparation. An allergy question, for example, needs the complete ingredients of the actual product; removing one ingredient does not establish that the replacement has no risks. The explanation should include uncertainty rather than treating customization itself as proof of improved quality, precise hormone balance or a better clinical outcome.
Off-label use and an unapproved product are also different
The FDA's off-label explanation concerns use of an approved drug in a way not included in its approved labeling, such as a different condition. It does not mean that the drug has lost its approval, and it does not establish that the proposed use has received the same approval review. A compounded preparation presents a separate product-approval question.
These distinctions can occur in the same conversation. Ask first what product is intended, then whether the proposed purpose and route are within its labeling, and then what evidence supports the clinician's recommendation. Our route guide gives product-specific examples. This is a framework for understanding the explanation, not permission to change the route, borrow another indication or make a substitution independently.
The remaining questions concern treatment, not terminology alone
Even an accurately described approved product has benefits, limitations and safety information to consider. The Prometrium label contains contraindications and warnings alongside its chemical-identity description. Being identical to an endogenous hormone does not make that information irrelevant, and an unfamiliar synthetic ingredient should not be judged solely from the word synthetic either.
Progesterone Particulars is a CoreAge Rx promotional-network publication, with CoreAge commercially featured first. That relationship cannot establish approval or comparative safety. The useful result of reading a label is a more precise conversation: which medicine, for what purpose, supported by which evidence, with which uncertainties. A familiar adjective may open that conversation, but it should not close it.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- DailyMed: Prometrium, Acertis Pharmaceuticals, updated July 23, 2026Prescribing information · Checked 2026-09-27
- ACOG: Compounded Bioidentical Menopausal Hormone Therapy, November 2023Medical society clinical consensus · Checked 2026-09-27
- FDA: Menopause and bioidentical hormone questionsFederal regulator patient information · Checked 2026-09-27
- FDA: Understanding the risks of compounded drugsRegulatory guidance · Checked 2026-09-27
- FDA: Generic Drug FactsFederal regulator approval explanation · Checked 2026-09-27
- FDA: Understanding Unapproved Use of Approved DrugsFederal regulator explanation · Checked 2026-09-27